{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/cancer-autoimmunity-addressing-clinical-and-operational-hurdles-car-t-cell-therapy#webpage",
"url": "https://www.fortrea.com/insights/cancer-autoimmunity-addressing-clinical-and-operational-hurdles-car-t-cell-therapy",
"name": "From cancer to autoimmunity: Addressing clinical and operational hurdles in CAR T-cell therapy expansion",
"description": "This Fortrea white paper explores the growing need for CAR T-cell therapy expansion and the challenges associated with improving patient access across oncology treatment environments. The content focuses on CAR T-cell therapy expansion, oncology treatment access, healthcare infrastructure considerations, broader patient reach, and factors affecting adoption of cell therapy approaches across clinical and healthcare settings. The white paper highlights challenges related to treatment accessibility, coordination requirements, healthcare system readiness, patient eligibility, and expanding access pathways for oncology patients who may benefit from CAR T-cell therapies. Fortrea discusses considerations affecting wider adoption of CAR T-cell therapies and the importance of improving accessibility across evolving oncology care environments. By integrating patient access considerations with broader oncology treatment planning and healthcare readiness approaches, the white paper provides insights into expanding access to CAR T-cell therapies for broader patient reach across oncology treatment programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "From cancer to autoimmunity: Addressing clinical and operational hurdles in CAR T-cell therapy expansion",
"item": "https://www.fortrea.com/insights/cancer-autoimmunity-addressing-clinical-and-operational-hurdles-car-t-cell-therapy"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/cancer-autoimmunity-addressing-clinical-and-operational-hurdles-car-t-cell-therapy#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/cancer-autoimmunity-addressing-clinical-and-operational-hurdles-car-t-cell-therapy#webpage"
},
"headline": "Expanding Access to CAR T-Cell Therapies for Broader Patient Reach | Fortrea White Paper",
"description": "This Fortrea white paper explores the growing need for CAR T-cell therapy expansion and the challenges associated with improving patient access across oncology treatment environments. The content focuses on CAR T-cell therapy expansion, oncology treatment access, healthcare infrastructure considerations, broader patient reach, and factors affecting adoption of cell therapy approaches across clinical and healthcare settings. The white paper highlights challenges related to treatment accessibility, coordination requirements, healthcare system readiness, patient eligibility, and expanding access pathways for oncology patients who may benefit from CAR T-cell therapies. Fortrea discusses considerations affecting wider adoption of CAR T-cell therapies and the importance of improving accessibility across evolving oncology care environments. By integrating patient access considerations with broader oncology treatment planning and healthcare readiness approaches, the white paper provides insights into expanding access to CAR T-cell therapies for broader patient reach across oncology treatment programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-11/car-t-therapy-expansion-cancer-to-autoimmunity.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-10-31",
"dateModified": "2025-10-31",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-10/car-t-cell-therapy-expansion.pdf",
"encodingFormat": "application/pdf"
}
}
]
}